GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.
GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...
WJET Erie on MSN3d
Drugmaker to settle nearly 80K Zantac lawsuits for up to $2.2 billionUK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level ...
GSK shares in London jumped 5% Thursday after the British drug giant said it has resolved most of the U.S. lawsuits it faced ...
GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer ...
The British pharmaceutical giant said Wednesday that it had struck agreements with 10 plaintiff firms aimed at resolving 93%, or about 80,000, of pending Zantac lawsuits in the country for up to ...
British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to lawsuits alleging that its Zantac heartburn drug caused cancer.
GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...
GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on ...
The deal settles 80,000 US court cases related to allegations that Zantac was contaminated with a suspected carcinogen.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback